These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 17357585)
1. New targets for putative neuroprotective agents. Jantas-Skotniczna D; Kajta M; Lasoń W Acta Pol Pharm; 2006; 63(5):359-68. PubMed ID: 17357585 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotection and immunomodulation by cell transplantation are becoming central themes in potential therapeutic approaches for cell-based therapies. Kocsis JD Neurosci Lett; 2009 Jun; 456(3):99. PubMed ID: 19429142 [No Abstract] [Full Text] [Related]
3. [Is good old minocycline a new neuroprotective drug?]. Melero-Fernández de Mera RM; García-Martínez E; Fernández-Gómez FJ; Hernández-Guijo JM; Aguirre N; Galindo MF; Jordán J Rev Neurol; 2008 Jul 1-15; 47(1):31-8. PubMed ID: 18592478 [TBL] [Abstract][Full Text] [Related]
4. Clinical trials in neuroprotection. Whitcup SM Prog Brain Res; 2008; 173():323-35. PubMed ID: 18929119 [TBL] [Abstract][Full Text] [Related]
5. Advancement of therapies for neuroprotection in multiple sclerosis. Lo A Expert Rev Neurother; 2008 Sep; 8(9):1355-66. PubMed ID: 18759548 [TBL] [Abstract][Full Text] [Related]
6. Combined 17beta-oestradiol and progesterone treatment prevents neuronal cell injury in cortical but not midbrain neurones or neuroblastoma cells. Lorenz L; Dang J; Misiak M; Tameh Abolfazl A; Beyer C; Kipp M J Neuroendocrinol; 2009 Oct; 21(10):841-9. PubMed ID: 19686448 [TBL] [Abstract][Full Text] [Related]
11. Linkage between immunomodulation, neuroprotection and neurogenesis. Aharoni R; Arnon R Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319 [TBL] [Abstract][Full Text] [Related]
12. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Barchet TM; Amiji MM Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842 [TBL] [Abstract][Full Text] [Related]
13. [Endogenous anticonvulsant and neuroprotective agents]. Lasoń W Przegl Lek; 2004; 61(11):1263-7. PubMed ID: 15727028 [TBL] [Abstract][Full Text] [Related]
14. Mitochondrial mechanisms of estrogen neuroprotection. Simpkins JW; Dykens JA Brain Res Rev; 2008 Mar; 57(2):421-30. PubMed ID: 17512984 [TBL] [Abstract][Full Text] [Related]
15. Impact of clinically relevant progestins on the neural effects of estradiol and the signaling pathways involved. Nilsen J; Deng J; Brinton RD Drug News Perspect; 2005 Nov; 18(9):545-53. PubMed ID: 16421627 [TBL] [Abstract][Full Text] [Related]
16. [Gene and gene cellular therapy and neurodegenerative diseases]. Ugriumov MV; Ermakov AS; Popov AP; Zhdanov RI Vopr Med Khim; 2000; 46(3):311-23. PubMed ID: 11033889 [TBL] [Abstract][Full Text] [Related]
17. Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system. Wang C; Slikker W Anesth Analg; 2008 Jun; 106(6):1643-58. PubMed ID: 18499593 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of hesperetin in mouse primary neurones are independent of CREB activation. Rainey-Smith S; Schroetke LW; Bahia P; Fahmi A; Skilton R; Spencer JP; Rice-Evans C; Rattray M; Williams RJ Neurosci Lett; 2008 Jun; 438(1):29-33. PubMed ID: 18467030 [TBL] [Abstract][Full Text] [Related]
19. History of neuroprotection and rationale as a therapy for glaucoma. Levin LA; Peeples P Am J Manag Care; 2008 Feb; 14(1 Suppl):S11-4. PubMed ID: 18284310 [TBL] [Abstract][Full Text] [Related]
20. Turning down, but not off. Lipton SA Nature; 2004 Apr; 428(6982):473. PubMed ID: 15057811 [No Abstract] [Full Text] [Related] [Next] [New Search]